Literature DB >> 8481411

Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry.

M L Reimer1, O A Mamer, A P Zavitsanos, A W Siddiqui, D Dadgar.   

Abstract

A sensitive and specific assay for the quantitative determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma specimens is described. Electron capture/negative ion chemical ionization gas chromatography/mass spectrometry is used to determine the extracted plasma concentrations of the three target compounds as their N-heptafluorobutyryl derivatives. Quantitation is performed by stable isotope dilution using d6-amphetamine and d6-methamphetamine as internal standards. Selected ion monitoring of the [M-HF]- ions of both the analytes and internal standards results in minimum quantifiable limits of 0.10 ng ml-1 for both amphetamine and methamphetamine and 0.25 ng ml-1 for desmethyldeprenyl. Excellent linearity (r = 0.998) up to at least 5.00 ng ml-1 is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481411     DOI: 10.1002/bms.1200220404

Source DB:  PubMed          Journal:  Biol Mass Spectrom        ISSN: 1052-9306


  9 in total

1.  Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration.

Authors:  A Lajtha; H Sershen; T Cooper; A Hashim; J Gaál
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

2.  Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457-Amphetamine Positron Emission Tomography Study.

Authors:  Rajesh Narendran; Neale Scott Mason; Michael L Himes; W Gordon Frankle
Journal:  Biol Psychiatry       Date:  2020-04-12       Impact factor: 13.382

3.  Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.

Authors:  W Gordon Frankle; Jennifer Paris; Michael Himes; N Scott Mason; Chester A Mathis; Rajesh Narendran
Journal:  Biol Psychiatry       Date:  2017-12-07       Impact factor: 13.382

Review 4.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Decreased prefrontal cortical dopamine transmission in alcoholism.

Authors:  Rajesh Narendran; Neale Scott Mason; Jennifer Paris; Michael L Himes; Antoine B Douaihy; W Gordon Frankle
Journal:  Am J Psychiatry       Date:  2014-08       Impact factor: 18.112

6.  A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum.

Authors:  Rajesh Narendran; N Scott Mason; Charles M Laymon; Brian J Lopresti; Natalie D Velasquez; Maureen A May; Steve Kendro; Diana Martinez; Chester A Mathis; W Gordon Frankle
Journal:  J Pharmacol Exp Ther       Date:  2010-01-26       Impact factor: 4.030

7.  Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study.

Authors:  R Narendran; H P Jedema; B J Lopresti; N S Mason; K Gurnsey; J Ruszkiewicz; C-M Chen; L Deuitch; W G Frankle; C W Bradberry
Journal:  Mol Psychiatry       Date:  2013-02-26       Impact factor: 15.992

8.  Cortical Dopamine Transmission as Measured with the [11C]FLB 457 - Amphetamine PET Imaging Paradigm Is Not Influenced by COMT Genotype.

Authors:  Rajesh Narendran; Divya Tumuluru; Maureen A May; Kodavali V Chowdari; Michael L Himes; Kelli Fasenmyer; W Gordon Frankle; Vishwajit L Nimgaonkar
Journal:  PLoS One       Date:  2016-06-20       Impact factor: 3.240

9.  Reproducibility of post-amphetamine [11C]FLB 457 binding to cortical D2/3 receptors.

Authors:  Rajesh Narendran; Michael Himes; N Scott Mason
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.